Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
2014
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Evolution of the Cancer Stem Cell Model
2014 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
EGFR Antagonists in Cancer Treatment
2008 Standout
Characteristics of Hodgkin's Lymphoma after Infectious Mononucleosis
2003
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
ROS in cancer therapy: the bright side of the moon
2020 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
2011
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
2015
Cancer stem cells revisited
2017 Standout
Pancreatic Adenocarcinoma
2014 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
2011 Standout
Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
2009 Standout
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
2017 Standout
Remodelling the extracellular matrix in development and disease
2014 Standout
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
Emerging Biological Principles of Metastasis
2017 Standout
Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations
2006
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Targeting metastasis
2016
Where next for gefitinib in patients with lung cancer?
2006
Emerging drugs for non-small-cell lung cancer
2007
VEGF Inhibition and Renal Thrombotic Microangiopathy
2008 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Cancer incidence in adolescents and young adults in the United States, 1992–1997
2003
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
2009
Natural polyphenols: An overview
2016 Standout
Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
2007
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
2006
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Risk Factors for Hodgkin's Lymphoma by EBV Status and Significance of Detection of EBV Genomes in Serum of Patients with EBV-Associated Hodgkin's Lymphoma
2003
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer
2008
2016 US lymphoid malignancy statistics by World Health Organization subtypes
2016 Standout
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta‐analysis of clinical trials
2012
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
2016 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
2007
Combination therapy in combating cancer
2017 Standout
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
2008 StandoutNobel
Phase II Data with ZD6474, a Small-Molecule Kinase Inhibitor of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor, in Previously Treated Advanced Non–Small-Cell Lung Cancer
2005
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
2007
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
2014
Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
2010
Works of Bethany Sleckman being referenced
Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
2009
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
2011
Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection.
1998
O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study
2005
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.
2012
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.
2013
ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial
2006